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Endosomal trafficking and degradation of epidermal
growth factor receptor (EGFR) play an essential role
in the control of its signaling. Phosphatidylinositol-
4,5-bisphosphate (PtdIns4,5P2) is an established
regulator of endocytosis, whereas PtdIns3P modu-
lates endosomal trafficking. However, we demon-
strate here that type I gamma phosphatidylinositol
phosphate 5-kinase i5 (PIPKIgi5), an enzyme that
synthesizes PtdIns4,5P2, controls endosome-to-
lysosome sorting of EGFR. In this pathway, PIPKIgi5
interacts with sorting nexin 5 (SNX5), a protein that
binds PtdIns4,5P2 and other phosphoinositides.
PIPKIgi5 and SNX5 localize to endosomes, and loss
of either protein blocks EGFR sorting into intralumi-
nal vesicles (ILVs) of the multivesicular body. Loss
of ILV sorting greatly enhances and prolongs EGFR
signaling. PIPKIgi5 and SNX5 prevent Hrs ubiquitina-
tion, and this facilitates the Hrs association with
EGFR that is required for ILV sorting. These findings
reveal that PIPKIgi5 and SNX5 form a signaling nexus
that controls EGFR endosomal sorting, degradation,
and signaling.
INTRODUCTION
Epidermal growth factor receptor (EGFR) is a critical component
of signaling pathways that govern cell growth and differentiation
during embryogenesis and adult homeostasis (Schlessinger,
2002). The regulated activation of EGFR is essential for normal
signaling, and loss of EGFR or its overactivation leads tomultiple
diseases (Casalini et al., 2004; Hynes and MacDonald, 2009).
Following epidermal growth factor (EGF) stimulation, EGFR
signaling is regulated by endocytic trafficking, where activated
EGFR is internalized, and trafficking determines the fate of inter-
nalized EGFR, including recycling back to the plasma mem-
brane, translocation to the nucleus, or trafficking to the lysosome
for degradation (Carpenter and Liao, 2009; Sorkin and Goh,
2009). Internalized EGFR continues to signal from endosomal
compartments until the agonist is separated from the receptor
or the agonist-receptor complex is sorted into intraluminal vesi-144 Developmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Icles (ILVs) of the multivesicular body (MVB) (McLaughlin et al.,
2002; Sorkin and von Zastrow, 2009). Sorting and lysosomal
degradation of activated EGFR are essential mechanisms to
control EGFR signaling (Sorkin and von Zastrow, 2009).
Phosphoinositides play fundamental roles in membrane re-
ceptor endocytosis and endosomal sorting. PtdIns4,5P2 is
predominantly at the plasma membrane, where it modulates
the formation of clathrin-coated pits and receptor endocytosis
(Barbieri et al., 2001; Jost et al., 1998). At endosomes, PtdIns3P
and PtdIns3,5P2 are synthesized and are key lipid messengers
for endosomal trafficking (Clague et al., 2009). Although
PtdIns4,5P2 is also synthesized on endosomal and lysosomal
membranes, a role for PtdIns4,5P2 in endosomal trafficking
has not been defined (Arneson et al., 1999; Watt et al., 2002).
Type I gamma phosphatidylinositol phosphate kinase (PIPKIg)
is an enzyme that synthesizes PtdIns4,5P2 by phosphorylation of
PtdIns4P (Heck et al., 2007; Schill and Anderson, 2009b). The
PIPKIg gene is alternatively spliced, resulting in protein variants
that contain unique extensions at the C terminus (Schill and
Anderson, 2009b; Xia et al., 2011). The individual PIPKIg exten-
sions mediate interactions with unique binding partners, often
PtdIns4,5P2 effectors, which target each PIPKIg splice variant
to distinct subcellular compartments necessary for the speci-
ficity in PtdIns4,5P2 signaling (Barlow et al., 2010; Heck et al.,
2007). Six PIPKIg variants have been identified in humans,
known as PIPKIgi1, i2, i3, i4, i5, and i6 (Schill and Anderson,
2009b; Xia et al., 2011). PIPKIgi1 is the shortest splicing variant
and is a major contributor to the PtdIns4,5P2 pool that supports
G-protein-coupled receptor-mediated inositol 1,4,5-trisphos-
phate generation and plays a critical role in Ca2+ flux (Wang
et al., 2004). PIPKIgi2 has a 28 amino acid C-terminal extension
that binds to the talin FERM domain (Di Paolo et al., 2002; Ling
et al., 2002) and regulates talin assembly, adhesion dynamics,
and migration (Sun et al., 2007). PIPKIgi2 also regulates protein
trafficking and cell polarity through interactions with the clathrin
adaptor protein complexes (AP) and the exocyst complex
(Bairstow et al., 2006; Ling et al., 2007; Thapa et al., 2012).
Recently, PIPKIgi4 and PIPKIgi5 were identified and found to
distinctively localize to the nucleus and endosomes, respec-
tively, but their biological functions are not defined (Schill and
Anderson, 2009b).
Here, we show that PIPKIgi5 interacts with sorting nexin 5
(SNX5), a phosphoinositide binding protein. Loss of PIPKIgi5 or
SNX5 results in a block of EGFR sorting into ILVs of the MVB
and in prolonged and enhanced EGFR signaling. The datanc.
Figure 1. PIPKIgi5 Controls EGFR Downregulation and Signaling
(A) The domain structure and sequence of the C termini of PIPKIgi1, i2 and i5.
(B) Two different siRNAs specific for PIPKIgi5 similarly blocked EGF-induced (10 nM) EGFR downregulation in MDA-MB-231 cells. The PIPKIgi5_1 siRNA was
used in further experiments.
(C–G) Control or PIPKIgi5-knockdown cells were treated with EGF (10 nM) for the times indicated (C). The EGFR protein level, EGFR activation, ERK activation,
and AKT activation were detected. The following were quantified: EGFR protein level (D), EGFR activation detected by phospho-tyr1068 antibody (E), ERK
activation (F), and AKT activation (G). Quantification of EGFR protein level and EGFR activation was normalized with tubulin level. Quantification of ERK or AKT
activation was normalized with total ERK or AKT level. The values shown on graphs represent the mean ± SEM from three independent experiments.
See also Figure S1.
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PIPKIgi5 Controls EGFR Lysosomal Sortinguncover a signaling nexus formed by PIPKIgi5, SNX5, and phos-
phoinositide generation that controls EGFR endosomal sig-
naling, sorting, and degradation.
RESULTS
PIPKIgi5 Controls EGFR Degradation and Signaling
The C-terminal extensions of PIPKIgi1, i2, and i5 are shown in
Figure 1A (Schill and Anderson, 2009b). PIPKIgi2 targets to
adhesions and plays key roles in EGFR-mediated cell migration
(Sun et al., 2007). To compare the roles of PIPKIgi5 and PIPKIgi2
in EGFR signaling, each variant was knocked down using iso-
form-specific small interfering RNAs (siRNAs). Strikingly, loss
of PIPKIgi5 blocked EGF-induced EGFR degradation (Figures
1B–1D). This was specific for PIPKIgi5 as loss of PIPKIgi2 (Fig-
ures S1A and S1B available online) or other variants (not shown)
had no impact on EGFR degradation. To rule out siRNA off-
target effects, two different PIPKIgi5 siRNAs, PIPKIgi5_1 and
PIPKIgi5_2, were used, and both knocked down PIPKIgi5 and
blocked EGFR downregulation (Figure 1B). Loss of PIPKIgi5 in
MDA-MB-231, A431, and SKBR3 cells blocked EGFR loss (Fig-
ures S1C–S1F), indicating that this is not a cell-type-specific role
for PIPKIgi5. To determine the impact of PIPKIgi5 knockdown onDeveEGFR activation, the autophosphorylation of EGFR on tyrosine
1068 was quantified. In cells lacking PIPKIgi5, the activation of
EGFR was enhanced and prolonged (Figures 1C and 1E). Con-
sistent with prolonged EGFR activation, both ERK and AKT acti-
vation were enhanced and prolonged (Figures 1C, 1F, and 1G) in
PIPKIgi5-knockdown cells. There was no significant change in
EGFR messenger RNA levels between control and PIPKIgi5-
knockdown cells (Figure S1G), signifying a role for PIPKIgi5 in
EGFR degradation. To determine if the role of PIPKIgi5 is depen-
dent on the level of EGFR stimulation, cells were stimulated with
a low EGF concentration (0.2 nM). Low EGF induced EGFR
degradation in control cells (Figure S1H). In PIPKIgi5-knock-
down cells, the degradation of EGFR induced by low EGF was
also blocked and EGFR activation and downstream AKT sig-
naling were enhanced and prolonged (Figure S1H).
To determine if PIPKIgi5 lipid kinase activity was required for
EGFR downregulation, a knockdown-rescue approach was
developed. Here, siRNA was used to knock down endogenous
PIPKIgi5, and then wild-type PIPKIgi5 or kinase dead mutant
(PIPKIgi5KD) vectors containing siRNA-resistant silent muta-
tions were re-expressed using lentivirus-mediated infection.
Expression of wild-type PIPKIgi5 but not PIPKIgi5KD rescued
EGFR degradation in PIPKIgi5-knockdown cells (Figures S1Ilopmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc. 145
Figure 2. PIPKIgi5 Controls EGFR Endosomal Trafficking
MDA-MB-231 cells were transfected with control siRNA or PIPKIgi5 siRNA separately and then stimulated with EGF (10 nM) for the times indicated.
(A) Immunofluorescence staining with EGFR and EEA1 antibodies.
(B and C) Quantification of EGFR-EEA1 colocalization 15 min (B) or 60 min (C) after EGF stimulation.
(D) Cells were pretreatedwith the lysosome inhibitor chloroquine (50 mM) for 2 hr to prevent the rapid degradation of EGFR, stimulatedwith EGF (10 nM) for 60min,
and then stained with EGFR and LAMP1 antibodies.
(E) Quantification of EGFR-LAMP1 colocalization 60 min after EGF stimulation. Error bars indicate mean ± SEM (n = 150 cells from three independent experi-
ments). Scale bar represents 10 mm. **p < 0.01.
See also Figure S2.
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degradation and indicate that kinase activity is required for
PIPKIgi5 control of EGFR downregulation.
PIPKIgi5 Controls EGFR Lysosomal Sorting
To clarify the trafficking step that requires PIPKIgi5 for
EGFR degradation, the uptake of Alexa Fluor 488-labeled EGF
(10 nM) was quantified by flow cytometry to track the internaliza-
tion of EGFR. Loss of PIPKIgi5 did not block EGFR internalization
(Figures S2A and S2B). After 5 min of EGF stimulation, the
amount of internalized EGF in PIPKIgi5-knockdown cells was
1.5-fold that in control cells (Figure S2B), which is consistent
with higher EGFR levels in PIPKIgi5-knockdown cells (Figure 1).
Low EGF (%2 ng/ml) treatment largely induces clathrin-medi-
ated endocytosis (CME) of EGFR, while high EGF also induces
nonclathrin endocytosis (Sigismund et al., 2008). CME is depen-
dent on PtdIns4,5P2 (Jost et al., 1998). To assess a role for
PIPKIgi5 in CME, the endocytosis of transferrin receptor, which
mainly undergoes CME, was studied. Knockdown of PIPKIgi5
did not affect transferrin receptor endocytosis (Figure S2C), indi-
cating that PIPKIgi5 is not required for CME.146 Developmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier ITo examine later sorting steps, the endosomal trafficking of
EGFR was investigated. This demonstrated that after EGF stim-
ulation, there was colocalization of EGFR with the early endo-
some marker early endosomal antigen 1 (EEA1) in both control
and PIPKIgi5-knockdown cells (Figures 2A and 2B). This indi-
cated that PIPKIgi5 knockdown did not alter EGFR trafficking
to the early endosome. However, 60 min after EGF stimulation,
EGFR-EEA1 colocalization in PIPKIgi5-knockdown cells was
significantly greater than in control cells (Figures 2A and 2C).
This indicated that loss of PIPKIgi5 impeded EGFR sorting
from the early endosome.
Under those same conditions, EGFR was also costained with
the late endosome/lysosome marker lysosomal-associated
membrane protein 1 (LAMP1). The trafficking of EGFR to the
lysosome indicated by EGFR-LAMP1 colocalization was dimin-
ished in PIPKIgi5-knockdown cells (Figures 2D and 2E). The
loss of EGFR trafficking to the late endosome/lysosome is
consistent with the decrease in EGFR degradation observed
following knockdown of PIPKIgi5.
Internalized EGFR can be recycled back to the plasma mem-
brane from early endosomes or the limiting membrane of MVBnc.
Figure 3. PIPKIgi5 Interacts with SNX5, and Both Localize to the Endosome
(A) MDA-MB-231 cells were subjected to immunoprecipitation with SNX5 antibody and then immunoblotted with antibodies as indicated.
(B) Recombinant GST-SNX5, GST-SNX5-PX, GST-SNX5-BAR, and full-length His6-PIPKIgi5 were purified from E. coli and subjected to GST pull-down assays.
(C) Hemagglutinin (HA)-tag fusion of PIPKIgi2, PIPKIgi5, or PIPKIgi5KD was coexpressed with Myc-SNX5, and HA antibody was used for immunoprecipitation
from cell lysates.
(D) Quantification of SNX5 interaction with PIPKIgi5 or PIPKIgi5KD (n = 3). Error bars indicate mean ± SEM. ***p < 0.001.
(E) Immunofluorescence staining of HA-PIPKIgi5 (green), Myc-SNX5 (blue), and internalized EGF (Alexa555-EGF, red).
(F) Immunofluorescence staining of HA-PIPKIgi5 (green), EEA1 (blue), and internalized EGF (Alexa555-EGF, red). Scale bar represents 10 mm.
IB, immunoblot; IgG, immunoglobulin G; IP, immunoprecipitation; WT, wild-type. See also Figure S3.
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EGFR trafficking from endosomes to lysosomes may enhance
receptor recycling; therefore, EGFR recycling was quantified.
As shown in Figures S2D–S2F, there was a significant increase
in internalized EGFR recycling back to the plasma membrane
in PIPKIgi5-knockdown cells.
PIPKIgi5 Interacts with SNX5
PIPKIg splice variants usually regulate biological functions by
associating with specific binding partners, often PtdIns4,5P2
effectors, via their distinct C termini (Heck et al., 2007). These
PIPKIg interactions lead to spatial generation of PtdIns4,5P2
that regulates specific effectors (Ling et al., 2002; Sun et al.,
2007; Thapa et al., 2012). To identify PIPKIgi5-binding partners,Devea yeast two-hybrid screen was performed using the C terminus
of PIPKIgi5 as bait. SNX5, a phosphoinositide-binding protein,
was identified as an interacting protein. SNX5 is composed of
a PX domain and a Bin/Amphiphysin/Rvs (BAR) domain. SNX5
is a component of the mammalian retromer complex and is an
endosomal trafficking protein (Wassmer et al., 2009). Addition-
ally, overexpression of SNX5 has been reported to inhibit
EGFR degradation (Liu et al., 2006), but the exact role of SNX5
in EGFR endosomal trafficking remains unclear. Endogenous
SNX5 was immunoprecipitated from cell lysates and examined
by western blot for association of PIPKIgi5. PIPKIgi5 was de-
tected with the SNX5 complex (Figure 3A). Direct binding was
confirmed using glutathione S-transferase (GST) pull-down
assays with GST-SNX5 and full-length His6-PIPKIgi5. PIPKIgi5lopmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc. 147
Figure 4. SNX5 Modulates EGFR Endoso-
mal Trafficking and Signaling
MDA-MB-231 Cells were transfected with control
or SNX5 siRNA separately and then stimulated
with EGF (10 nM) for the times indicated.
(A) Phosphorylation and degradation of EGFR,
AKT, and ERK activation in control and SNX5-
knockdown cells were detected by western
blotting.
(B) Quantification of EGFR protein level.
(C) Quantification of EGFR activation with an
antibody toward phospho-tyr1068.
(D) Quantification of AKT activation.
(E) Quantification of ERK activation (n = 3). Error
bars indicate mean ± SEM.
(F) Immunofluorescence staining with EGFR and
EEA1 antibodies on control and SNX5-knockdown
cells.
(G) Quantification of EGFR-EEA1 colocalization.
(H) Control and SNX5-knockdown cells were pre-
treated with chloroquine (50 mM), stimulated with
EGF (10 nM), and then stained with EGFR and
LAMP1 antibodies.
(I) Quantification of EGFR-LAMP1 colocalization.
Error bars indicate mean ± SEM. **p < 0.01 (n =
150 cells from three independent experiments).
Scale bar represents 10 mm.
See also Figure S4.
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domain in vitro (Figure 3B).
PIPKIgi5, but not PIPKIgi2 (Figure 3C) or other variants (not
shown), was coimmunoprecipitated with SNX5. This result
demonstrated that the unique C terminus of PIPKIgi5 is required
for its association with SNX5. Although EGF did not regulate the
interaction (Figures 3C and 3D), the PIPKIgi5KD interaction with
SNX5 was diminished compared to wild-type PIPKIgi5 (Figures
3C and 3D). This indicates that PIPKIgi5 kinase activity regulates
the PIPKIgi5-SNX5 interaction. Consistent with their physical
association, PIPKIgi5 and SNX5 colocalize in cells (Figure 3E).
SNX5 targets to early endosomes (Merino-Trigo et al., 2004)
with PIPKIgi5 (Figure 3F), and kinase activity is required for
PIPKIgi5 localization, as PIPKIgi5KD did not colocalize with148 Developmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc.EEA1 (Figure S3A). These results suggest
a role for PIPKIgi5 and SNX5 at endo-
somes. PIPKIgi2 did not colocalize with
EEA1 (Figure S3A), indicating that this tar-
geting is PIPKIgi5 specific. In contrast,
SNX5 was not sufficient for the localiza-
tion of PIPKIgi5 to endosomes, as
PIPKIgi5 still localized to endosomes in
cells lacking SNX5 (Figure S3B).
SNX5 Controls EGFR Sorting and
Downregulation
To examine the role of SNX5 in EGFR
sorting, the expression of SNX5 was
knocked down. Loss of SNX5 blocked
EGF-stimulated EGFR degradation (Fig-
ures 4A and 4B), demonstrating that
SNX5 is required. Knockdown of SNX5also enhanced and prolonged activation of EGFR, AKT, and
ERK (Figures 4A–4E) similar to PIPKIgi5 knockdown. In SNX5-
knockdown cells, the endosomal trafficking of EGFR was inves-
tigated to determine if loss of SNX5 resulted in a phenotype
analogous to the PIPKIgi5 knockdown. Knockdown of SNX5
did not impact EGFR trafficking to early endosomes (Figures
4F and 4G), but did block trafficking to the late endosome/lyso-
some (Figures 4H and 4I). This phenotype is indistinguishable
from that of PIPKIgi5 loss, demonstrating that SNX5 is also
required for EGFR lysosomal trafficking.
SNX5 is a component of the retromer complex that regulates
retrograde trafficking of cation-independent mannose-6-phos-
phate receptor (CI-MPR) from the endosome to the trans-Golgi
network (TGN) (Hara et al., 2008; Wassmer et al., 2007). The
Figure 5. PIPKIgi5 and SNX5 Are Required
for EGFR Sorting into ILVs of the MVB
MDA-MB-231 cells were transfected with control,
PIPKIgi5 siRNA, or SNX5 siRNA separately, and
then the cells were treated with or without EGF
(10 nM) for 1 hr and used in the EM study.
(A) MVBs in different siRNA-transfected cells are
shown. An MVB containing immunogold-labeled
EGFR was seen in EGF-treated cells.
(B) Knockdown efficiency of PIPKIgi5 and SNX5
was confirmed via western blot.
(C) Amount of immunogold-labeled EGFR in the
MVB lumen or limiting membrane in EGF-treated
cells was quantified.
(D) The number of ILVs in each MVB was quanti-
fied. Error bars indicate mean ± SEM. **p < 0.01;
***p < 0.001 (n = 60 MVBs from three independent
experiments for each siRNA treatment). Scale bar
represents 200 nm.
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SNX dimer. To determine if the role of SNX5 in modulating EGFR
degradation is dependent on retromer function, two other key
retromer components, Vps26 and Vps35, were knocked down
and the impact on EGFR degradation was quantified. Loss of
Vps26 or Vps35 did not impact EGFR degradation (Figures
S4A and S4B), indicating that retromer function is not required
for EGFR degradation. The above data suggest that PIPKIgi5
and SNX5 function together to modulate EGFR trafficking, and
we explored the role in downregulation of other receptors.
Activation of c-Met by hepatocyte growth factor or PAR1 acti-
vation by thrombin also results in receptor degradation in the
lysosome (Gullapalli et al., 2006; Hammond et al., 2001). Down-
regulation of c-Met (Figures S4C and S4D) or PAR1 (Figures S4E
and S4F) was unaffected by PIPKIgi5 loss. Similarly, the knock-
down of SNX5 blocked the degradation of EGFR, while the
degradation of c-Met or PAR1 was not affected (Figures S4G–
S4J). This indicates that PIPKIgi5 and SNX5 may modulate the
lysosomal sorting of a subset of receptors and that loss of
PIPKIgi5 or SNX5 does not disrupt the general function of the
endolysosomal system.
PIPKIgi5 and SNX5 Are Required for EGFR Sorting into
ILVs of the MVB
PIPKIgi5 and SNX5 are required for EGFR trafficking from endo-
some to lysosome for degradation (Figures 2 and 4). The sortingDevelopmental Cell 25, 144–1of EGFR into ILVs of the MVB is required
for its lysosomal sorting and degradation
(Eden et al., 2009). To define the role for
PIPKIgi5 or SNX5 in EGFR ILV sorting,
an electron microscopy (EM) approach
was used. Cells were serum starved and
then treated with or without EGF (10 nM)
for 1 hr. EGF treatment has been shown
to stimulate the formation of ILVs and
EGFR sorting into ILVs (Eden et al.,
2009; White et al., 2006). As shown in Fig-
ure 5, EGF-induced ILV formation was
decreased in PIPKIgi5- or SNX5-knock-down cells. The ILV sorting of EGFR in EGF-treated cells was
tracked via anti-EGFR antibody and 10 nm protein A-gold (see
Experimental Procedures). In PIPKIgi5- or SNX5-knockdown
cells, the quantity of EGFR was greater at the limiting membrane
of theMVBwith reduced EGFR in ILVs (Figure 5). This indicates a
defect in sorting of EGFR from the limiting membrane to ILVs in
PIPKIgi5- or SNX5-knockdown cells.
PIPKIgi5 and Phosphoinositides Modulate Interactions
among SNX5, Hrs, and EGFR
Membrane containing EGFR invaginates from the limiting mem-
brane of the MVB to form ILVs, a process dependent on the
endosomal sorting complex required for transport (ESCRT)
(Katzmann et al., 2002). Hrs is a key component of ESCRT-0
(Henne et al., 2011) that binds to ubiquitinated EGFR and recruits
additional ESCRT components to mediate EGFR sorting into
ILVs (Eden et al., 2009). Similar to knockdown of PIPKIgi5 or
SNX5, Hrs knockdown leads to a defect in EGFR sorting from
MVB-limiting membrane to ILVs (Razi and Futter, 2006). To
determine if PIPKIgi5 and SNX5 modulate EGFR sorting to
ILVs via an Hrs-mediated pathway, the effect of their loss on
the Hrs-EGFR interaction was explored. Knockdown of either
PIPKIgi5 or SNX5 resulted in a loss of the interaction of EGFR
with Hrs (Figures 6A and 6B).
SNX5 associates with Hrs and was coimmunoprecipitated
with endogenous Hrs (Figure 6C). Further, the SNX5-Hrs55, April 29, 2013 ª2013 Elsevier Inc. 149
Figure 6. SNX5 and PIPKIgi5 Modulate
EGFR-Hrs Interaction
(A) MDA-MB-231 cells were transfected with
control, PIPKIgi5 siRNA, or SNX5 siRNA, and the
effects on EGFR-Hrs interaction were assessed
via coimmunoprecipitation assay.
(B) Quantification of the EGFR-Hrs interaction
(n = 3). Error bars indicate mean ± SEM.
***p < 0.001.
(C) MDA-MB-231 cells expressing wild-type
PIPKIgi5, PIPKIgi5KD, or PIPKIgi2 were estab-
lished by lentivirus infection. Cells were trans-
fected with control or PIPKIgi5 siRNA, and the
effects on the SNX5-Hrs interaction were evalu-
ated via coimmunoprecipitation assay.
(D) Interaction of purified His6-SNX5 and GST-Hrs
was measured in a solid-phase binding assay with
or without PtdIns4P, PtdIns3P, or PtdIns4,5P2 as
indicated.
(E) Quantification of Hrs-SNX5 interaction in the
solid-phase binding assay. (n = 3). Error bars
indicate mean ± SEM.
See also Figure S5.
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ished the SNX5-Hrs interaction (Figure 6C). The SNX5-Hrs
interaction was rescued by re-expression of PIPKIgi5 but not
PIPKIgi5KD (Figure 6C), indicating that PIPKIgi5 kinase activity
is required for the SNX5-Hrs interaction. Expression of PIPKIgi2
could not rescue the SNX5-Hrs interaction (Figure 6C), indicating
that this function is PIPKIgi5 specific.
Multiple phosphoinositides, including PtdIns3P and
PtdIns4,5P2, have been shown to bind to SNX5 (Koharudin
et al., 2009; Pylypenko et al., 2007; van Weering et al., 2010).
To determine if PtdIns4,5P2 modulates the SNX5-Hrs interac-
tion, a solid-phase-based in vitro binding assay was used with
purified recombinant SNX5 and Hrs. As shown in Figures 6D
and 6E, addition of PtdIns4,5P2 or PtdIns3P greatly enhanced
the SNX5-Hrs interaction. This result suggests that PtdIns4,5P2
production by PIPKIgi5 modulates the SNX5-Hrs interaction,
which is consistent with the loss of SNX5-Hrs interaction
observed after PIPKIgi5 knockdown. PtdIns4P had a minimal
effect on the SNX5-Hrs interaction compared with PtdIns4,5P2
or PtdIns3P, indicating a specificity of phosphoinositides in
modulating the SNX5-Hrs interaction (Figures 6D and 6E).
To explore the targeting of SNX5 to endosomes, Hrs or
PIPKIgi5 was knocked down. This did not significantly change
SNX5 targeting (Figure S5A). These data indicate that150 Developmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc.PtdIns4,5P2 generation alone does not
control SNX5 endosomal targeting. How-
ever, inhibition of PI3K impedes SNX5
endosomal targeting, indicating a role
for PtdIns3P generation in this process
(Figures S5B and S5C). These combined
results indicate that SNX5 may be regu-
lated by multiple phosphoinositides.
These results suggest that both
PtdIns3P and PtdIns4,5P2 play critical
roles in modulating SNX5 function at
endosomes. To assess if phosphoinosi-tide binding is required for the SNX5modulation of EGFR sorting,
we used a structure-function approach to define SNX5 binding
to phosphoinositides. Though PX domains of SNXs primarily
bind to PtdIns3P (Carlton et al., 2005), the structure of the
SNX5-PX domain was solved by nuclear magnetic resonance
and X-ray crystallography, and this method found that SNX5-
PX interacted with PtdIns4,5P2 (Koharudin et al., 2009). R42/
K44/K46 are positively charged and form a sequence found in
the SNX5 PX domain critical for PtdIns4,5P2 binding (Koharudin
et al., 2009). These positively charged residues were mutated to
the similar, but uncharged, glutamine. This mutant was named
SNX5_PX3. A PIP strip assay showed that wild-type SNX5
protein could bind to multiple phosphoinositides, including
PtdIns3P and PtdIns4,5P2 (Figure S6C). The PX domain of
SNX5_PX3 is defective in PtdIns4,5P2 binding (data not shown).
Unexpectedly, the full-length SNX5_PX3 protein still retained the
ability to bind PtdIns4,5P2 via a PIP strip assay (Figure S6C). This
indicates that the BAR domain of SNX5 is also capable of inter-
acting with PtdIns4,5P2.
It was reported that with SNX9, mutations of specific resi-
dues in the BAR domain inhibited its phosphoinositide binding
and function (Pylypenko et al., 2007). Using a sequence and
structural homology approach with SNX9 (see Figure S6A), res-
idues were mutated (K224E/R235E/K324E/K328E/R330E) in the
Figure 7. SNX5 and PIPKIgi5 Modulate Hrs
Ubiquitination
(A) MDA-MB-231 cells were transfected with
control, PIPKIgi5 siRNA, or SNX5 siRNA. Cells
were then treated with EGF (10 nM) for 15min, and
the ubiquitination of EGFR was measured.
(B) MDA-MB-231 cells were transfected with or
without Myc-SNX5 combined with control or
PIPKIgi5 siRNA, and the effects on Hrs ubiquiti-
nation were detected.
(C) HA-Hrs was coexpressed with Myc-SNX5 or
Myc-SNX5_B5, and the Hrs-SNX5 interaction was
detected via coimmunoprecipitation assay.
(D) MDA-MB-231 cells were transfected with
b-galactosidase (control), Myc-SNX5, or Myc-
SNX5_B5, and the effects on Hrs ubiquitination
were detected.
(E) HA-NEDD-4-1 and Myc-Hrs was coexpressed
with Myc-SNX5 or Myc-SNX5_B5, and the Hrs
interaction with NEDD-4-1 was detected via
coimmunoprecipitation assay.
(F) MDA-MB-231 cell lines expressing wild-type
SNX5 or SNX5_B5 were established by lentivirus
infection. Cells were transfected with control or
SNX5 siRNA and then stimulated with EGF (10 nM)
for 60 min. The expression of EGFR or SNX5
protein was detected with specific antibodies
compared to the actin loading control.
(G) Rescue effect of SNX5 or SNX5_B5 on EGFR
downregulation in SNX5 siRNA-transfected cells
was quantified. Error bars indicate mean ± SEM.
***p < 0.001 (n = 3).
(H) Model for PIPKIgi5 and SNX5 regulation of
EGFR endosomal trafficking and degradation.
PIPKIgi5 directly interacts with SNX5 and gener-
ates PtdIns4,5P2, which modulates SNX5-Hrs
interaction. The SNX5-Hrs interaction inhibits
NEDD-4 recruitment to Hrs and blocks Hrs ubiq-
uitination and facilitates Hrs interaction with EGFR
to initiate EGFR sorting to ILVs for downstream
lysosomal degradation.
See also Figure S6.
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phosphoinositide binding, including decreased binding to
PtdIns4,5P2 and PtdIns3P (Figure S6C). The abundance of pos-
itive charges along the concave face of the BAR domain is
conducive to binding negatively charged lipid membrane sur-
faces (Frost et al., 2009). Consistently, by liposome binding
assay, full-length SNX5 could bind to multiple phosphoinositi-
des, including PtdIns4,5P2, PtdIns3P, and other PtdInsPn iso-
mers (Figure S6F).
PIPKIgi5, Phosphoinositides, and SNX5 Modulate Hrs
Ubiquitination
The interaction between Hrs and EGFR is required for lysosomal
sorting, and these interactions are regulated by ubiquitination of
Hrs and EGFR (Eden et al., 2009; Komada and Kitamura, 2005;
Sorkin andGoh, 2009; Zwang and Yarden, 2009). The ubiquitina-
tion of EGFR is required for interaction with Hrs and EGFR sort-
ing to the ILV (Eden et al., 2012). EGFR ubiquitination was not
inhibited by loss of PIPKIgi5 or SNX5 (Figure 7A). Ubiquitination
of Hrs inhibits its ability to interact with ubiquitinated cargos such
as EGFR (Hoeller et al., 2006). SNX5 overexpression blocked HrsDeveubiquitination, and this required PIPKIgi5 (Figure 7B). Consis-
tently, loss of PIPKIgi5 dramatically decreased the interaction
of SNX5 with Hrs (Figure 6C) and increased Hrs ubiquitination
(Figure 7B). These data indicate that PIPKIgi5 and SNX5 together
regulate the ubiquitination of Hrs and thus the interaction of Hrs
with EGFR (Figures 6A and 6B), an interaction required for sort-
ing of EGFR to the ILV (Eden et al., 2012).
PIPKIgi5 and SNX5 did not regulate c-Met or PAR1 degrada-
tion (Figures S4C–S4J), and loss of Hrs also did not impact
c-Met or PAR1 degradation (Figures S4G–S4J), but Hrs is
required for EGFR degradation (Eden et al., 2012). This suggests
that PIPKIgi5, SNX5, and Hrs form a nexus that regulates EGFR
degradation. Phosphoinositides regulate the SNX5-Hrs interac-
tion (Figure 6D), and this interaction blocks Hrs ubiquitination
(Figure 7B). In vitro, SNX5 and SNX5_B5 indistinguishably
interact with Hrs without phosphoinositides (data not shown),
while the addition of PtdIns4,5P2 or PtdIns3P did not enhance
Hrs-SNX5_B5 interaction (Figures S6D and S6E). This is consis-
tent with the finding that SNX5_B5 lost phosphoinositides bind-
ing (Figure S6C). In vivo, SNX5_B5 interacts poorly with Hrs
compared to wild-type (Figure 7C). Expression of SNX5 but notlopmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc. 151
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tent with the data showing that SNX5 interaction with Hrs is regu-
lated by phosphoinositide binding.
The E3 ubiquitin ligase NEDD-4-1 ubiquitinates Hrs, and this
ubiquitination inhibits Hrs interaction with ubiquitinated EGFR
(Hoeller et al., 2006; Katz et al., 2002; Lin et al., 2010). NEDD-
4-1 interacts with Hrs, but this interaction is reduced upon
expression of SNX5 but not the SNX5_B5 mutant (Figure 7E).
As the interaction of NEDD-4-1 is required for Hrs ubiquitination,
this defines a mechanism for SNX5 control of Hrs ubiquitination
(Hoeller et al., 2006; Katz et al., 2002; Lin et al., 2010).
To determine if SNX5 requires phosphoinositide binding for
EGFR sorting and degradation, a knockdown and rescue assay
was established. This approach demonstrated that SNX5
rescued the EGFR degradation defect in SNX5-knockdown cells
but the SNX5_B5 mutant did not (Figures 7F and 7G). This is
consistent with the deficiency of SNX5_B5 to interact with Hrs
in vivo and its inability to modulate Hrs ubiquitination. These
data are consistent with a model in which PIPKIgi5 directly
interacts with SNX5 and subsequent PtdIns4,5P2 generation
enhances the SNX5-Hrs interaction. The SNX5-Hrs interaction
inhibits NEDD-4-1 recruitment to Hrs and blocks Hrs ubiquitina-
tion. Thus, PIPKIgi5 and SNX5 collaborate to facilitate Hrs
interactionwith ubiquitinated EGFR,which initiates EGFR sorting
to ILVs for subsequent lysosomal degradation (Figure 7H).
DISCUSSION
PtdIns3P plays essential roles in the trafficking of EGFR and
other receptors through the endosomal and lysosomal pathway
(Clague et al., 2009; de Lartigue et al., 2009; Lindmo and Sten-
mark, 2006; Sorkin and Goh, 2008). We have shown that
PIPKIgi5 and its kinase activity are also required for EGFR sort-
ing to the ILVs of the MVB, supporting a role for PtdIns4,5P2 in
EGFR endosomal trafficking. Hrs, a PtdIns3P binding protein,
also binds ubiquitinated EGFR and is required for sorting
EGFR to ILVs (Sorkin and Goh, 2008). PIPKIgi5, SNX5, and
PtdIns4,5P2 synthesis regulates the interaction of EGFR with
Hrs by regulating the ubiquitination of Hrs, a process known to
block the interaction of Hrs with EGFR (Hoeller et al., 2006). As
the Hrs interaction with EGFR is essential for EGFR sorting to
ILVs, this represents a key regulatory step in this pathway (see
Figure 7H).
PtdIns4,5P2 modulates many biological processes, including
adhesion and cytoskeletal dynamics (Ling et al., 2006), vesicular
trafficking (Downes et al., 2005), secretion (Martin, 2001), ion
channel regulation (Delmas et al., 2005), nuclear signaling, and
gene expression (Barlow et al., 2010; Mellman et al., 2008).
These activities are regulated by PtdIns4,5P2 synthesis at
diverse subcellular sites (Barlow et al., 2010; Heck et al., 2007).
The PH domain of PLCd fused to GFP (PLCd-PH-GFP) has
been used as a PtdIns4,5P2-specific probe, and it primarily
detects PtdIns4,5P2 at the plasma membrane (Botelho et al.,
2000; Va´rnai and Balla, 1998). It is clear that PLCd-PH does
not detect all cellular PtdIns4,5P2, for example at focal adhe-
sions or in the nucleus (Barlow et al., 2010; Ling et al., 2002).
Consistently, we have not been able to detect PtdIns4,5P2
at EGFR-containing endosomes with PLCd-PH-GFP (data not
shown).152 Developmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier IThe inability to detect PtdIns4,5P2 at some compartments
may be explained by a low abundance of PtdIns4,5P2 or by the
mechanism of PIP kinase signaling at these sites. The specificity
of PtdIns4,5P2 signaling can be regulated by PIP kinase interac-
tions with PtdIns4,5P2 effectors (Anderson et al., 1999; El
Sayegh et al., 2007; Heck et al., 2007; Li et al., 2012; Ling
et al., 2002, 2007; Mellman et al., 2008; Schill and Anderson,
2009a; Thapa et al., 2012). For this mechanism, we and others
have been unable to show a targeting of the PtdIns4,5P2-specific
PLCd-PH-GFP to locations where the PIP kinases function,
including focal adhesions, vesicles for trafficking, and the
nucleus (Li et al., 2012; Ling et al., 2002, 2007; Mellman et al.,
2008; Sun et al., 2007; Thapa et al., 2012). Potentially, the abun-
dance of PtdIns4,5P2 at these sites is low because the
PtdIns4,5P2 is bound to effector proteins. Using biochemical
approaches, PtdIns4,5P2 has previously been shown to be syn-
thesized on late endosomes and lysosomes (Arneson et al.,
1999; Watt et al., 2002). Recently, it was found that PtdIns4,5P2
is present at autolysosomes and regulates autophagic lysosome
reformation (Rong et al., 2012). The combined results support
PtdIns4,5P2 generation on endosome/lysosome membranes.
PIPKIg isoforms use PtdIns4P as substrate to synthesize
PtdIns4,5P2 (Anderson et al., 1999). Type II phosphatidylinositol
4-kinase (type II PI-4K) a and b are enzymes that synthesize
PtdIns4P and can be targeted to endosomes (Balla et al.,
2002), indicating that the PIPKIg substrate is present at endo-
somes. Consistent with this role, the type II PI-4Ka has been
reported to modulate EGFR trafficking to the late endosome
(Minogue et al., 2006). OCRL, a PtdIns4,5P2 5-phosphatase, is
reported to function at endosomes (Vicinanza et al., 2011).
Loss of OCRL leads to a decrease of EGFR degradation (Vici-
nanza et al., 2011), indicating that both PIPKIgi5 and OCRL,
the enzymes producing and destroying PtdIns4,5P2, respec-
tively, play roles in EGFR degradation.
Multiple phosphoinositide phosphate isomers bind to SNX5,
including PtdIns3P, PtdIns3,4P2, and PtdIns4,5P2 (Koharudin
et al., 2009; Liu et al., 2006; Merino-Trigo et al., 2004). Our results
are consistent, indicating that SNX5 binds to multiple phosphoi-
nositides through different sites on both the PX and BAR
domains. Our results indicate that PtdIns3P and PtdIns4,5P2
bind to SNX5 and promote its interaction with Hrs (see Figure 6).
SNX5 is a component of the mammalian retromer (Wassmer
et al., 2007, 2009) that controls trafficking between the endo-
some and the TGN (Bonifacino and Hurley, 2008). The retromer
is composed of SNX5 and SNX6 in association with SNX1 and
SNX2, and these SNXs form complexes with the cargo recogni-
tion trimer composed of Vps26, Vps29, and Vps35 (Bonifacino
and Hurley, 2008). Loss of Vps26 or Vps35 did not impact
EGFR lysosomal degradation (Figure S4), indicating that retro-
mer function was not involved. Yet, overexpression of SNX5
inhibited EGFRdegradation (Liu et al., 2006), possibly by disrupt-
ing endogenous interactions with other components. Similarly,
Hrs mediates EGFR degradation (Lloyd et al., 2002), but its over-
expression also inhibited EGFR degradation (Chin et al., 2001).
SNX1 and SNX2 may influence the lysosomal sorting of internal-
ized EGFR, but neither protein is essential for this process (Gul-
lapalli et al., 2004). The loss of SNX5, SNX6, or both in HeLa cells
was shown to also diminish SNX1 protein levels (Wassmer et al.,
2007). In MDA-MB-231 cells, knockdown of SNX5 does notnc.
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down of SNX1 or SNX2 resulted in loss of SNX5 (but not SNX6),
resulting in a block of EGF-stimulated EGFR degradation (un-
published data). Knockdown of SNX6 also decreased SNX1
and SNX2 and blocked EGFR degradation (unpublished data).
These results are consistent with the assembly of SNX1, SNX2,
SNX5, and SNX6 into a dynamic complex (Wassmer et al.,
2009) that stabilizes the proteins within the complex. These
SNXs bind phosphoinositides, target to the endosome, and
may function together in EGFR endosomal trafficking.
PIPKIgi5, SNX5, andHrs regulate the degradation of EGFR but
not c-Met or PAR1. This suggests that PIPKIgi5, SNX5, and Hrs
work in a common pathway that is receptor selective. Previous
findings support receptor-specificmechanisms for the formation
of ILVs in theMVB (Babst, 2011;White et al., 2006). For example,
the sorting of PAR1 into ILVs of the MVB is independent of Hrs
(Dores et al., 2012). This supports a model where multiple path-
ways control receptor sorting into ILVs. The PIPKIgi5 pathway
has significant implications for EGFR signaling, as the EGFR
remains active as it travels through the endosomal pathway.
Changes in expression or regulation of PIPKIgi5, SNX5, or Hrs
are positioned to regulate EGFR degradation and signaling. As
EGFR plays key roles in cancer biology, therapeutic modulation
of this pathway represents a mechanism to control the magni-
tude and duration of EGFR signaling. Further, this pathway
may control the cellular content of EGFR, a key factor in EGFR
control of autophagic cell death (Weihua et al., 2008).
EXPERIMENTAL PROCEDURES
Lentivirus Constructs
Generation of replication-defective infectious viral particles and the transduc-
tion of the cells were carried out following the protocol provided by Addgene
and Invitrogen. In brief, Myc-tagged SNX5 constructs containing silence
mutations in the SNX5 siRNA targeting region were cloned into MluI and SalI
sites of PWPT vector (Addgene). Hemagglutinin-tagged PIPKIgi5 constructs
containing silence mutations in the PIPKIgi5 siRNA targeting region were
cloned into pLenti6.3 vector (Invitrogen) following the company’s instructions.
Stbl3 competent cells (Invitrogen) were used for transformation and DNA
purification to minimize the mutagenesis.
Electron Microscopy
The EGFR trafficking into the MVB was detected via EM as described previ-
ously (Bache et al., 2006; Hanafusa et al., 2011). MDA-MB-231 cells treated
with control or PIPKIgi5 siRNA were serum starved. The cells were then
labeled with LA22 EGFR antibody (Millipore) at 4C for 20 min and washed
thrice, followed by 20 min incubation with 10 nm protein A-gold (Electron
Microscopy Sciences). After washing, the cells were treated with EGF
(10 nM) for 60 min at 37C. Cells then were fixed in 0.1 M sodium cacodylate
containing 2.0% paraformaldehyde and 2.5% glutaraldehyde. The mor-
phology of the MVB was visualized by a JOEL100CX transmission electron
microscope at the UW Medical School EM Facility. Three separate experi-
ments were performed for each treatment, and >2,000 mm2 of cytoplasm
was examined in each case. More than 60 MVBs were examined for statistical
analysis for each treatment.
Immunoprecipitation and Immunoblotting
Immunoprecipitation was performed as described previously (Ling et al.,
2003). Briefly, 24 hr after transfection, MDA-MB-231 cells were starved with
serum-free Dulbecco’s modified Eagle’s medium (DMEM) overnight and
then stimulated with or without 10 nM EGF for 15 min. Then cells were har-
vested and lysed in 25 mM HEPES (pH 7.2), 150 mM NaCl, 0.5% NP-40,
1 mM MgCl2, and protease inhibitor cocktail and then centrifuged and incu-Devebated with protein G Sepharose and 2 mg antibody as indicated at 4C for
4 hr. The immunocomplexes were separated by SDS-PAGE and analyzed as
indicated.
Immunofluorescence
Cells were resuspended and then plated on the coverslips in DMEM with
10% fetal bovine serum, allowed to adhere for 4 hr, and then starved in
serum-free DMEM for 2 hr. Then, cells were stimulated with 10 nM EGF for a
different time course and fixed by 4%paraformaldehyde. Then, cells were per-
meablized with 0.5% Triton X-100 and blocked by 3% BSA in PBS at room
temperature for 30 min, incubated with the primary antibody overnight at
4C, washed with 0.1% Triton X-100 in PBS, incubated with fluorescence-
labeled secondary antibody at room temperature for 30 min, and then washed
with 0.1% Triton X-100 in PBS. Cells were maintained and examined using a
603 Plan oil immersion lens on an inverted microscope (Eclipse TE200-U,
Nikon). Images were processed as described previously (Ling et al., 2002)
using Photoshop 7.0.
Quantification of Colocalization
The background-subtracted imageswere segmented using aminimal intensity
of EEA1- or LAMP1-labeled vesicles as a low threshold. The integrated voxel
intensity of EGFR in the segmented image was considered as EGFR localized
in EEA1- or LAMP1-labeled vesicles, respectively. The extent of colocalization
was calculated as the ratio of the integrated EGFR fluorescence of the
segmented image to the total fluorescence of the same fluorochromes.
Solid-Phase Binding Assay
This assay was performed as described previously (Martel et al., 2001). Micro-
titer plates (96 wells; MaxiSorp Immuno Plate, Nunc) were coated overnight at
4C with 1 mg of His6-SNX5 per well in a final volume of 200 ml in PBS and sub-
sequently blocked with 1% fatty-acid-free BSA in PBS for 1 hr at room temper-
ature. The plates were then incubated with or without PtdIns4,5P2 or PtdIns3P
in a final volume of 200 ml in PBS for 30 min at room temperature. Then plates
were incubated with GST-Hrs (1 mg in 200 ml PBS) for 1 hr at room temperature.
The wells were then washed three times with PBS containing 1% fatty-acid-
free BSA, and bound protein was removed by the addition of 40 ml of Laemmli
sample buffer followed by incubation of the microtiter plate at 95C for 7 min.
In Vivo Ubiquitination Assay
The ubiquitination of Hrs was evaluated as described previously (Pan and
Chen, 2003). His6-ubiquitin-conjugated Hrs in MDA-MB-231 cells was purified
by Ni2+-nitrilotriacetic acid (NTA) beads. MDA-MB-231 cell was lysed in IP
buffer (25 mM HEPES [pH 7.2], 150 mM NaCl, 0.5% NP-40, 1 mM MgCl2,
and protease inhibitor cocktail) and incubated with Ni2+-NTA beads (QIAGEN)
for 2 hr at 4C. The beads were washed with IP buffer, buffer A (8 M urea, 0.1M
Na2PO4/NaH2PO4, 0.01 M Tris-HCl [pH 8.0], and 10 mM b-mercaptoethanol),
and buffer B (8 M urea, 0.1 M Na2PO4/NaH2PO4, 0.01 M Tris-HCl [pH 6.3], and
10 mM b-mercaptoethanol), and bound proteins were eluted with buffer C
(200 mM imidazole, 0.15 M Tris-HCl [pH 6.7], 30% glycerol, 0.72 M b-mercap-
toethanol, and 5% SDS). The eluted proteins were analyzed by western blot-
ting for the presence of His6-ubiquitin-conjugated Hrs via using anti-Hrs
antibody.
Statistics
All data analysis was performed using SigmaPlot. Bar graphs represent
means ± SEM, as indicated. Statistical significance was assessed using the
Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.devcel.2013.03.010.
ACKNOWLEDGMENTS
We thank Suyong Choi, Rakesh Singh, Narendra Thapa, and Weimin Li for
discussions. This work is supported by National Institutes of Health (NIH)lopmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc. 153
Developmental Cell
PIPKIgi5 Controls EGFR Lysosomal Sortinggrant CA104708 (to R.A.A.); American Heart Association grants to Y.S. (award
12SDG11950022), N.J.S. (award 0610121Z), and A.C.H (award PRE2280534);
a Howard Hughes Medical Institute International Student Research fellowship
(to X.T.); and NIH fellowship T32 GMGM08688 (to A.C.H. and N.J.S.).
Received: July 29, 2012
Revised: January 24, 2013
Accepted: March 15, 2013
Published: April 18, 2013
REFERENCES
Anderson, R.A., Boronenkov, I.V., Doughman, S.D., Kunz, J., and Loijens, J.C.
(1999). Phosphatidylinositol phosphate kinases, a multifaceted family of
signaling enzymes. J. Biol. Chem. 274, 9907–9910.
Arneson, L.S., Kunz, J., Anderson, R.A., and Traub, L.M. (1999). Coupled ino-
sitide phosphorylation and phospholipase D activation initiates clathrin-coat
assembly on lysosomes. J. Biol. Chem. 274, 17794–17805.
Babst, M. (2011). MVB vesicle formation: ESCRT-dependent, ESCRT-inde-
pendent and everything in between. Curr. Opin. Cell Biol. 23, 452–457.
Bache, K.G., Stuffers, S., Malerød, L., Slagsvold, T., Raiborg, C., Lechardeur,
D., Wa¨lchli, S., Lukacs, G.L., Brech, A., and Stenmark, H. (2006). The ESCRT-
III subunit hVps24 is required for degradation but not silencing of the epidermal
growth factor receptor. Mol. Biol. Cell 17, 2513–2523.
Bairstow, S.F., Ling, K., Su, X., Firestone, A.J., Carbonara, C., and Anderson,
R.A. (2006). Type Igamma661 phosphatidylinositol phosphate kinase directly
interacts with AP2 and regulates endocytosis. J. Biol. Chem. 281, 20632–
20642.
Balla, A., Tuymetova, G., Barshishat, M., Geiszt, M., and Balla, T. (2002).
Characterization of type II phosphatidylinositol 4-kinase isoforms reveals
association of the enzymes with endosomal vesicular compartments. J. Biol.
Chem. 277, 20041–20050.
Barbieri, M.A., Heath, C.M., Peters, E.M., Wells, A., Davis, J.N., and Stahl, P.D.
(2001). Phosphatidylinositol-4-phosphate 5-kinase-1beta is essential for
epidermal growth factor receptor-mediated endocytosis. J. Biol. Chem. 276,
47212–47216.
Barlow, C.A., Laishram, R.S., and Anderson, R.A. (2010). Nuclear phosphoino-
sitides: a signaling enigma wrapped in a compartmental conundrum. Trends
Cell Biol. 20, 25–35.
Bonifacino, J.S., and Hurley, J.H. (2008). Retromer. Curr. Opin. Cell Biol. 20,
427–436.
Botelho, R.J., Teruel, M., Dierckman, R., Anderson, R., Wells, A., York, J.D.,
Meyer, T., and Grinstein, S. (2000). Localized biphasic changes in phosphati-
dylinositol-4,5-bisphosphate at sites of phagocytosis. J. Cell Biol. 151, 1353–
1368.
Carlton, J., Bujny, M., Rutherford, A., and Cullen, P. (2005). Sorting nexins—
unifying trends and new perspectives. Traffic 6, 75–82.
Carpenter, G., and Liao, H.J. (2009). Trafficking of receptor tyrosine kinases to
the nucleus. Exp. Cell Res. 315, 1556–1566.
Casalini, P., Iorio, M.V., Galmozzi, E., and Me´nard, S. (2004). Role of HER
receptors family in development and differentiation. J. Cell. Physiol. 200,
343–350.
Chin, L.S., Raynor, M.C., Wei, X., Chen, H.Q., and Li, L. (2001). Hrs interacts
with sorting nexin 1 and regulates degradation of epidermal growth factor
receptor. J. Biol. Chem. 276, 7069–7078.
Clague, M.J., Urbe´, S., and de Lartigue, J. (2009). Phosphoinositides and the
endocytic pathway. Exp. Cell Res. 315, 1627–1631.
de Lartigue, J., Polson, H., Feldman, M., Shokat, K., Tooze, S.A., Urbe´, S., and
Clague, M.J. (2009). PIKfyve regulation of endosome-linked pathways. Traffic
10, 883–893.
Delmas, P., Coste, B., Gamper, N., and Shapiro,M.S. (2005). Phosphoinositide
lipid second messengers: new paradigms for calcium channel modulation.
Neuron 47, 179–182.154 Developmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier IDi Paolo, G., Pellegrini, L., Letinic, K., Cestra, G., Zoncu, R., Voronov, S.,
Chang, S., Guo, J., Wenk, M.R., and De Camilli, P. (2002). Recruitment and
regulation of phosphatidylinositol phosphate kinase type 1 gamma by the
FERM domain of talin. Nature 420, 85–89.
Dores, M.R., Chen, B., Lin, H., Soh, U.J., Paing, M.M., Montagne, W.A.,
Meerloo, T., and Trejo, J. (2012). ALIX binds a YPX(3)L motif of the GPCR
PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sorting. J. Cell
Biol. 197, 407–419.
Downes, C.P., Gray, A., and Lucocq, J.M. (2005). Probing phosphoinositide
functions in signaling andmembrane trafficking. Trends Cell Biol. 15, 259–268.
Eden, E.R., White, I.J., and Futter, C.E. (2009). Down-regulation of epidermal
growth factor receptor signalling within multivesicular bodies. Biochem. Soc.
Trans. 37, 173–177.
Eden, E.R., Huang, F., Sorkin, A., and Futter, C.E. (2012). The role of EGF
receptor ubiquitination in regulating its intracellular traffic. Traffic 13, 329–337.
El Sayegh, T.Y., Arora, P.D., Ling, K., Laschinger, C., Janmey, P.A., Anderson,
R.A., and McCulloch, C.A. (2007). Phosphatidylinositol-4,5 bisphosphate pro-
duced by PIP5KIgamma regulates gelsolin, actin assembly, and adhesion
strength of N-cadherin junctions. Mol. Biol. Cell 18, 3026–3038.
Frost, A., Unger, V.M., and De Camilli, P. (2009). The BAR domain superfamily:
membrane-molding macromolecules. Cell 137, 191–196.
Gullapalli, A., Garrett, T.A., Paing, M.M., Griffin, C.T., Yang, Y., and Trejo, J.
(2004). A role for sorting nexin 2 in epidermal growth factor receptor down-
regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein
trafficking. Mol. Biol. Cell 15, 2143–2155.
Gullapalli, A., Wolfe, B.L., Griffin, C.T., Magnuson, T., and Trejo, J. (2006). An
essential role for SNX1 in lysosomal sorting of protease-activated receptor-1:
evidence for retromer-, Hrs-, and Tsg101-independent functions of sorting
nexins. Mol. Biol. Cell 17, 1228–1238.
Hammond, D.E., Urbe´, S., Vande Woude, G.F., and Clague, M.J. (2001).
Down-regulation of MET, the receptor for hepatocyte growth factor.
Oncogene 20, 2761–2770.
Hanafusa, H., Ishikawa, K., Kedashiro, S., Saigo, T., Iemura, S., Natsume, T.,
Komada, M., Shibuya, H., Nara, A., and Matsumoto, K. (2011). Leucine-rich
repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor.
Nat. Commun. 2, 158.
Hara, S., Kiyokawa, E., Iemura, S., Natsume, T., Wassmer, T., Cullen, P.J.,
Hiai, H., and Matsuda, M. (2008). The DHR1 domain of DOCK180 binds to
SNX5 and regulates cation-independent mannose 6-phosphate receptor
transport. Mol. Biol. Cell 19, 3823–3835.
Heck, J.N., Mellman, D.L., Ling, K., Sun, Y., Wagoner, M.P., Schill, N.J., and
Anderson, R.A. (2007). A conspicuous connection: structure defines function
for the phosphatidylinositol-phosphate kinase family. Crit. Rev. Biochem.
Mol. Biol. 42, 15–39.
Henne, W.M., Buchkovich, N.J., and Emr, S.D. (2011). The ESCRT pathway.
Dev. Cell 21, 77–91.
Hoeller, D., Crosetto, N., Blagoev, B., Raiborg, C., Tikkanen, R., Wagner, S.,
Kowanetz, K., Breitling, R., Mann, M., Stenmark, H., and Dikic, I. (2006).
Regulation of ubiquitin-binding proteins by monoubiquitination. Nat. Cell
Biol. 8, 163–169.
Hynes, N.E., and MacDonald, G. (2009). ErbB receptors and signaling path-
ways in cancer. Curr. Opin. Cell Biol. 21, 177–184.
Jost, M., Simpson, F., Kavran, J.M., Lemmon, M.A., and Schmid, S.L. (1998).
Phosphatidylinositol-4,5-bisphosphate is required for endocytic coated
vesicle formation. Curr. Biol. 8, 1399–1402.
Katz, M., Shtiegman, K., Tal-Or, P., Yakir, L., Mosesson, Y., Harari, D.,
Machluf, Y., Asao, H., Jovin, T., Sugamura, K., and Yarden, Y. (2002).
Ligand-independent degradation of epidermal growth factor receptor involves
receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif
targets ubiquitylation by Nedd4. Traffic 3, 740–751.
Katzmann, D.J., Odorizzi, G., and Emr, S.D. (2002). Receptor downregulation
and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3, 893–905.
Koharudin, L.M., Furey,W., Liu, H., Liu, Y.J., andGronenborn, A.M. (2009). The
phox domain of sorting nexin 5 lacks phosphatidylinositol 3-phosphatenc.
Developmental Cell
PIPKIgi5 Controls EGFR Lysosomal Sorting(PtdIns(3)P) specificity and preferentially binds to phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2). J. Biol. Chem. 284, 23697–23707.
Komada, M., and Kitamura, N. (2005). The Hrs/STAM complex in the downre-
gulation of receptor tyrosine kinases. J. Biochem. 137, 1–8.
Li, W., Laishram, R.S., Ji, Z., Barlow, C.A., Tian, B., and Anderson, R.A. (2012).
Star-PAP control of BIK expression and apoptosis is regulated by nuclear
PIPKIa and PKCd signaling. Mol. Cell 45, 25–37.
Lin, Q., Wang, J., Childress, C., Sudol, M., Carey, D.J., and Yang, W. (2010).
HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal
growth factor (EGF)-induced degradation of EGF receptor and ACK. Mol. Cell.
Biol. 30, 1541–1554.
Lindmo, K., and Stenmark, H. (2006). Regulation of membrane traffic by phos-
phoinositide 3-kinases. J. Cell Sci. 119, 605–614.
Ling, K., Doughman, R.L., Firestone, A.J., Bunce, M.W., and Anderson, R.A.
(2002). Type I gamma phosphatidylinositol phosphate kinase targets and reg-
ulates focal adhesions. Nature 420, 89–93.
Ling, K., Doughman, R.L., Iyer, V.V., Firestone, A.J., Bairstow, S.F., Mosher,
D.F., Schaller, M.D., and Anderson, R.A. (2003). Tyrosine phosphorylation of
type Igamma phosphatidylinositol phosphate kinase by Src regulates an integ-
rin-talin switch. J. Cell Biol. 163, 1339–1349.
Ling, K., Schill, N.J., Wagoner, M.P., Sun, Y., and Anderson, R.A. (2006).
Movin’ on up: the role of PtdIns(4,5)P(2) in cell migration. Trends Cell Biol.
16, 276–284.
Ling, K., Bairstow, S.F., Carbonara, C., Turbin, D.A., Huntsman, D.G., and
Anderson, R.A. (2007). Type I gamma phosphatidylinositol phosphate kinase
modulates adherens junction and E-cadherin trafficking via a direct interaction
with mu 1B adaptin. J. Cell Biol. 176, 343–353.
Liu, H., Liu, Z.Q., Chen, C.X., Magill, S., Jiang, Y., and Liu, Y.J. (2006). Inhibitory
regulation of EGF receptor degradation by sorting nexin 5. Biochem. Biophys.
Res. Commun. 342, 537–546.
Lloyd, T.E., Atkinson, R., Wu, M.N., Zhou, Y., Pennetta, G., and Bellen, H.J.
(2002). Hrs regulates endosome membrane invagination and tyrosine kinase
receptor signaling in Drosophila. Cell 108, 261–269.
Martel, V., Racaud-Sultan, C., Dupe, S., Marie, C., Paulhe, F., Galmiche, A.,
Block, M.R., and Albiges-Rizo, C. (2001). Conformation, localization, and
integrin binding of talin depend on its interaction with phosphoinositides.
J. Biol. Chem. 276, 21217–21227.
Martin, T.F. (2001). PI(4,5)P(2) regulation of surface membrane traffic. Curr.
Opin. Cell Biol. 13, 493–499.
McLaughlin, S., Wang, J., Gambhir, A., and Murray, D. (2002). PIP(2) and pro-
teins: interactions, organization, and information flow. Annu. Rev. Biophys.
Biomol. Struct. 31, 151–175.
Mellman, D.L., Gonzales, M.L., Song, C., Barlow, C.A., Wang, P., Kendziorski,
C., and Anderson, R.A. (2008). A PtdIns4,5P2-regulated nuclear poly(A) poly-
merase controls expression of select mRNAs. Nature 451, 1013–1017.
Merino-Trigo, A., Kerr, M.C., Houghton, F., Lindberg, A., Mitchell, C.,
Teasdale, R.D., and Gleeson, P.A. (2004). Sorting nexin 5 is localized to a sub-
domain of the early endosomes and is recruited to the plasma membrane
following EGF stimulation. J. Cell Sci. 117, 6413–6424.
Minogue, S., Waugh, M.G., De Matteis, M.A., Stephens, D.J., Berditchevski,
F., and Hsuan, J.J. (2006). Phosphatidylinositol 4-kinase is required for endo-
somal trafficking and degradation of the EGF receptor. J. Cell Sci. 119,
571–581.
Pan, Y., and Chen, J. (2003). MDM2 promotes ubiquitination and degradation
of MDMX. Mol. Cell. Biol. 23, 5113–5121.
Pylypenko, O., Lundmark, R., Rasmuson, E., Carlsson, S.R., and Rak, A.
(2007). The PX-BAR membrane-remodeling unit of sorting nexin 9. EMBO J.
26, 4788–4800.
Razi, M., and Futter, C.E. (2006). Distinct roles for Tsg101 and Hrs in multive-
sicular body formation and inward vesiculation. Mol. Biol. Cell 17, 3469–3483.
Rong, Y., Liu, M., Ma, L., Du, W., Zhang, H., Tian, Y., Cao, Z., Li, Y., Ren, H.,
Zhang, C., et al. (2012). Clathrin and phosphatidylinositol-4,5-bisphosphate
regulate autophagic lysosome reformation. Nat. Cell Biol. 14, 924–934.DeveSchill, N.J., and Anderson, R.A. (2009a). Out, in and back again: PtdIns(4,5)P(2)
regulates cadherin trafficking in epithelial morphogenesis. Biochem. J. 418,
247–260.
Schill, N.J., and Anderson, R.A. (2009b). Two novel phosphatidylinositol-4-
phosphate 5-kinase type Igamma splice variants expressed in human cells
display distinctive cellular targeting. Biochem. J. 422, 473–482.
Schlessinger, J. (2002). Ligand-induced, receptor-mediated dimerization and
activation of EGF receptor. Cell 110, 669–672.
Sigismund, S., Argenzio, E., Tosoni, D., Cavallaro, E., Polo, S., and Di Fiore,
P.P. (2008). Clathrin-mediated internalization is essential for sustained EGFR
signaling but dispensable for degradation. Dev. Cell 15, 209–219.
Sorkin, A., and Goh, L.K. (2008). Endocytosis and intracellular trafficking of
ErbBs. Exp. Cell Res. 314, 3093–3106.
Sorkin, A., and Goh, L.K. (2009). Endocytosis and intracellular trafficking of
ErbBs. Exp. Cell Res. 315, 683–696.
Sorkin, A., and von Zastrow, M. (2009). Endocytosis and signalling: intertwin-
ing molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609–622.
Sorkin, A., Krolenko, S., Kudrjavtceva, N., Lazebnik, J., Teslenko, L.,
Soderquist, A.M., and Nikolsky, N. (1991). Recycling of epidermal growth fac-
tor-receptor complexes in A431 cells: identification of dual pathways. J. Cell
Biol. 112, 55–63.
Sun, Y., Ling, K., Wagoner, M.P., and Anderson, R.A. (2007). Type I gamma
phosphatidylinositol phosphate kinase is required for EGF-stimulated direc-
tional cell migration. J. Cell Biol. 178, 297–308.
Thapa, N., Sun, Y., Schramp, M., Choi, S., Ling, K., and Anderson, R.A. (2012).
Phosphoinositide signaling regulates the exocyst complex and polarized
integrin trafficking in directionally migrating cells. Dev. Cell 22, 116–130.
van Weering, J.R., Verkade, P., and Cullen, P.J. (2010). SNX-BAR proteins in
phosphoinositide-mediated, tubular-based endosomal sorting. Semin. Cell
Dev. Biol. 21, 371–380.
Va´rnai, P., and Balla, T. (1998). Visualization of phosphoinositides that
bind pleckstrin homology domains: calcium- and agonist-induced dynamic
changes and relationship to myo-[3H]inositol-labeled phosphoinositide pools.
J. Cell Biol. 143, 501–510.
Vicinanza, M., Di Campli, A., Polishchuk, E., Santoro, M., Di Tullio, G., Godi, A.,
Levtchenko, E., De Leo, M.G., Polishchuk, R., Sandoval, L., et al. (2011). OCRL
controls trafficking through early endosomes via PtdIns4,5P2-dependent
regulation of endosomal actin. EMBO J. 30, 4970–4985.
Wang, Y.J., Li, W.H., Wang, J., Xu, K., Dong, P., Luo, X., and Yin, H.L. (2004).
Critical role of PIP5KIgamma87 in InsP3-mediated Ca(2+) signaling. J. Cell
Biol. 167, 1005–1010.
Wassmer, T., Attar, N., Bujny, M.V., Oakley, J., Traer, C.J., and Cullen, P.J.
(2007). A loss-of-function screen reveals SNX5 and SNX6 as potential compo-
nents of the mammalian retromer. J. Cell Sci. 120, 45–54.
Wassmer, T., Attar, N., Harterink, M., vanWeering, J.R., Traer, C.J., Oakley, J.,
Goud, B., Stephens, D.J., Verkade, P., Korswagen, H.C., and Cullen, P.J.
(2009). The retromer coat complex coordinates endosomal sorting and
dynein-mediated transport, with carrier recognition by the trans-Golgi net-
work. Dev. Cell 17, 110–122.
Watt, S.A., Kular, G., Fleming, I.N., Downes, C.P., and Lucocq, J.M. (2002).
Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the
pleckstrin homology domain of phospholipase C delta1. Biochem. J. 363,
657–666.
Weihua, Z., Tsan, R., Huang, W.C., Wu, Q., Chiu, C.H., Fidler, I.J., and Hung,
M.C. (2008). Survival of cancer cells is maintained by EGFR independent of its
kinase activity. Cancer Cell 13, 385–393.
White, I.J., Bailey, L.M., Aghakhani, M.R., Moss, S.E., and Futter, C.E. (2006).
EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular
endosome subpopulation. EMBO J. 25, 1–12.
Xia, Y., Irvine, R.F., and Giudici, M.L. (2011). Phosphatidylinositol 4-phosphate
5-kinase Ig_v6, a new splice variant found in rodents and humans. Biochem.
Biophys. Res. Commun. 411, 416–420.
Zwang, Y., and Yarden, Y. (2009). Systems biology of growth factor-induced
receptor endocytosis. Traffic 10, 349–363.lopmental Cell 25, 144–155, April 29, 2013 ª2013 Elsevier Inc. 155
